Maravai LifeSciences Market Sentiment

Maravai LifeSciences Holdings Inc

MRVINASDAQ

Trade with Public

$7.32

0.253.54%

最終更新: Oct 23, 4:00 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

決算: Q3 2026 Q3 2026のこれから水 11 4thの11 日後決算、マーケットクローズ後。

Maravai LifeSciences Market Sentiment - Benzinga

Maravai LifeSciences Market Sentiment

Market sentiment signals for Maravai LifeSciences (MRVI): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 11.0% short float

Options Flow▲ 0.03 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

12 analysts

Options Flow (P/C)

0.03

More calls — Bullish

58 calls · 2 puts

Avg Consensus PT

-19.1%

Highest Price Target

$10

+36.6%

Stifel

Lowest Price Target

-72.7%

Baird

Short Interest

11.0%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Sep 9, 2026	UBS	Dan Brennan—	+9.3%	$3 → $8	Maintained	Neutral
Aug 7, 2026	Wells Fargo	Evan Stampler—	-11.2%	$6 → $7	Maintained	Overweight
May 8, 2026	Wells Fargo	Brandon Couillard—	-24.9%	$5 → $6	Maintained	Overweight
Dec 15, 2025	Wells Fargo	Brandon Couillard—	-38.5%	$4 → $5	Maintained	Overweight
Aug 12, 2025	Craig-Hallum	Christian Schwab—	-31.7%	$10 → $5	Maintained	Buy
Aug 12, 2025	RBC Capital	Conor McNamara—	-31.7%	$7 → $5	Maintained	Outperform
May 13, 2025	Craig-Hallum	Christian Schwab—	+36.6%	$12 → $10	Maintained	Buy
May 13, 2025	Baird	Catherine Schulte—	-72.7%	$3 → $2	Maintained	Neutral
Mar 25, 2025	Morgan Stanley	Tejas Savant—	-31.7%	$7 → $5	Maintained	Equal-Weight
Mar 21, 2025	UBS	Dan Brennan—	-65.8%	$8 → $3	Maintained	Neutral
Mar 3, 2025	B of A Securities	Michael Ryskin—	+9.3%	$9 → $8	Maintained	Buy
Feb 26, 2025	Baird	Catherine Schulte—	-59.0%	$9 → $3	Downgrade	Outperform→Neutral
Dec 5, 2024	Goldman Sachs	Matthew Sykes—	-41.9%	$7 → $4	Downgrade	Neutral→Sell
Nov 14, 2024	Wolfe Research	Doug Schenkel—	—	—	Initiate	Peer Perform
Nov 8, 2024	RBC Capital	Conor McNamara—	+77.6%	$17 → $13	Maintained	Outperform
Nov 8, 2024	William Blair	Matt Larew—	—	—	Downgrade	Outperform→Market Perform
Nov 8, 2024	Baird	Catherine Schulte—	+23.0%	$10 → $9	Maintained	Outperform
Oct 8, 2024	Goldman Sachs	Matthew Sykes—	-4.4%	$8 → $7	Maintained	Neutral
Aug 27, 2024	Wells Fargo	Brandon Couillard—	+36.6%	$10	Initiate	Overweight
Aug 16, 2024	RBC Capital	Conor McNamara—	+104.9%	$15 → $15	Maintained	Outperform
Aug 13, 2024	Morgan Stanley	Tejas Savant—	+36.6%	$11 → $10	Downgrade	Overweight→Equal-Weight
Aug 8, 2024	Goldman Sachs	Matthew Sykes—	+9.3%	$7 → $8	Maintained	Neutral
Aug 8, 2024	UBS	Dan Brennan—	+50.3%	$9 → $11	Maintained	Neutral
Jul 9, 2024	Goldman Sachs	Matthew Sykes—	-4.4%	$8 → $7	Maintained	Neutral
May 9, 2024	Baird	Catherine Schulte—	+36.6%	$8 → $10	Maintained	Outperform